Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 4/20 | 0.50 |
| ▸ | CA2 | P00918 | 1/20 | 0.50 |
| ▸ | CA4 | P22748 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | TLR4 | O00206 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 3/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | CASP1 | P29466 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6913491 | 1.00 | CA1 (0.50) | CA1CA2CA4KMT2ACYP2D6 | |
| SCHEMBL919145 | 1.00 | CA1 (0.50) | CA1CA2CA4KMT2ACYP2D6 | |
| SCHEMBL2690167 | 0.98 | KMT2A (0.52) | CA1CA2CA4KMT2ACYP2D6 | |
| SCHEMBL20337323 | 0.98 | KMT2A (0.52) | CA1CA2CA4KMT2ACYP2D6 | |
| SCHEMBL2690883 | 0.93 | — | — | |
| SCHEMBL17427855 | 0.93 | — | — | |
| SCHEMBL765417 | 0.93 | — | — | |
| SCHEMBL2693006 | 0.82 | — | — | |
| SCHEMBL12895014 | 0.82 | CA1 (0.46) | CA1CA2CA4KMT2ACYP2D6 | |
| SCHEMBL10734273 | 0.82 | CA1 (0.46) | CA1CA2CA4KMT2ACYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230206644-A1 | PYRAZOLOPYRIMIDINE COMPOUNDS AS JAK INHIBITORS | GENENTECH, INC. (US) | 2023-06-29 | — | — | US | disclosed |
| US-20200339604-A1 | PYRAZOLOPYRIMIDINE COMPOUNDS AS JAK INHIBITORS | GENENTECH, INC. (US) | 2020-10-29 | — | — | US | disclosed |
| US-20170145028-A1 | ACC INHIBITORS AND USES THEREOF | GILEAD APOLLO, LLC (US) | 2017-05-25 | — | — | US | disclosed |
| EP-1808427-A2 | Novel processes for the preparation of bicyclic aminoalcohols | SHIONOGI & CO., LTD. (JP) | 2007-07-18 | — | — | EP | disclosed |
| US-6720439-B1 | EFFICIENT REDUCTION OF BASE SENSITIVE CARBONYL COMPOUNDS; SEPARATING RACEMIC CARBONYL COMPOUNDS; CHIRAL CATALYSTS | NAGOYA INDUSTRIAL SCIENCE RESEARCH INSTITUTE (JP) | 2004-04-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170145028-A1 | ACC INHIBITORS AND USES THEREOF | ACACA, ACACB, ACAT2 | CA1 1230/4885CA2 1428/4885CA4 1320/4885 |
| US-20200339604-A1 | PYRAZOLOPYRIMIDINE COMPOUNDS AS JAK INHIBITORS | JAK2, JAK1, JAK3 | CA1 4818/4885CA2 4521/4885CA4 4778/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.